Search Results
Sep 04, 2026, 07:00 ET Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
unresectable or metastatic HCC."ACE723 is an investigational GPC3-targeted dual-payload ADC developed through Acepodia's proprietary AD2C platform, which integrates expertise in antibody engineering, medicinal chemistry and tumor biology. GPC3 is a tumor-associated antigen frequently expressed in HCC,
More news about: Acepodia, Inc.
Sep 01, 2026, 08:30 ET Genuine Parts Company to Present at the 2026 Goldman Sachs Global Consumer and Retail Conference
ATLANTA, Sept. 1, 2026 /PRNewswire/ -- Genuine Parts Company (NYSE: GPC), a leading global service provider of automotive and industrial replacement parts and value-added solutions, announced today that Will Stengel, Chairman
More news about: Genuine Parts Company
Aug 27, 2026, 09:13 ET GPC Infrastructure Strengthens Leadership Team and Board to Support Continued Growth
GPC Infrastructure (GPC), an owner and operator of modular onsite power systems that help data center developers overcome grid interconnection delays, today announced
More news about: GPC Infrastructure
Aug 18, 2026, 20:15 ET CARsgen Therapeutics Announces 2026 Interim Results
against CLL1 for AML; KJ-C2526 against NKG2DL for AML, other malignancies and senescence; KJ-C2527 against Claudin18.2 for G/GEJA, etc.; KJ-C2630 against GPC3 for hepatocellular carcinoma (HCC), etc.Development of In Vivo CAR T-Cell ProductsCARsgen
More news about: CARsgen Therapeutics
Aug 11, 2026, 16:30 ET Genuine Parts Company Declares Regular Quarterly Dividend
ATLANTA, Aug. 11, 2026 /PRNewswire/ -- Genuine Parts Company (NYSE: GPC), a leading global service provider of automotive and industrial replacement parts and value-added solutions, announced today its Board of Directors declared
More news about: Genuine Parts Company
Aug 11, 2026, 08:04 ET Nitro™ Launches Nicotine-Free Performance Pouches Featuring Cognizin® Citicoline
calories, nicotine, or the need for a beverage. Each pouch contains Nitro's proprietary Paxatine™ Performance Blend, combining Cognizin® Citicoline with Alpha-GPC, caffeine, and essential B vitamins to support both physical energy and mental performance."Consumers increasingly want products that do more
More news about: Kyowa Hakko U.S.A
Jul 31, 2026, 02:15 ET CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
Walvax Biotechnology to jointly conduct an Investigator-Initiated Trial (IIT) for a hepatocellular carcinoma indication using mRNA-LNP-based in vivo GPC3-CAR therapy. This study is based on a preclinical study reported by the same team in the 2025 ASCO meeting. This partnership leverages CellOrigin's
More news about: CellOrigin
Jul 23, 2026, 10:10 ET AbelZeta announces publication in Nature journal highlighting clinical findings for an armored autologous GPC3 CAR-T therapy in patients with advanced hepatocellular carcinoma
Nature sharing the results of the first-in-human clinical study evaluating the safety and efficacy of C-CAR031, a novel glypican-3 (GPC3)-targeted CAR-T that AbelZeta and AstraZeneca previously partnered to develop in China, and which is now being developed solely by AstraZeneca as AZD7003.
More news about: AbelZeta Pharma, Inc.
Jul 21, 2026, 06:55 ET Genuine Parts Company Reports Second Quarter 2026 Results; Reaffirms 2026 Outlook for Adjusted EPS of $7.50 to $8.00
OutlookATLANTA, July 21, 2026 /PRNewswire/ -- Genuine Parts Company (NYSE: GPC), a leading global service provider of automotive and industrial replacement parts and value-added solutions, announced today its results for the second
More news about: Genuine Parts Company
Jul 13, 2026, 06:53 ET CancerFax Builds Trusted India-China Pathway for Advanced Cancer Treatment Access
with China emerging as an important market and research hub.Research activity is also growing in solid tumor CAR-T targets such as Claudin18.2, GPC3, B7-H3, and CEA, although patient suitability in these areas remains highly case-specific and dependent on hospital review. TIL therapy is another advanced
More news about: CancerFax
Jul 10, 2026, 08:43 ET Axiom Foods and NNB Nutrition Partner to Advance Functional "Protein+" Plant-Based Nutrition Trend
alternativeNNB's beverage products include:DL 185® a dipeptide for protein effectivenessGeniusPure® Alpha-GPC for cognitive performanceHydroPrime® for hydrationMitoBurn® for metabolic healthMitoPrime®
More news about: Axiom Foods
Jun 30, 2026, 08:30 ET Genuine Parts Company to Report Second Quarter 2026 Results on July 21, 2026
ATLANTA, June 30, 2026 /PRNewswire/ -- Genuine Parts Company (NYSE: GPC), a leading global service provider of automotive and industrial replacement parts and value-added solutions, plans to release second quarter financial
More news about: Genuine Parts Company
Jun 29, 2026, 13:30 ET Plopii lanza sobres nootrópicos para la concentración sin nicotina, potenciados con paraxantina
concentración, con un perfil más suave para el sueño, la ansiedad y la tolerancia.La fórmula combina paraxantina con 60 mg de alfa-GPC, 60 mg de citicolina y 60 mg de L-teanina, una combinación diseñada para favorecer la atención y una energía tranquila y concentrada durante todo el
More news about: Plopii Inc.
Jun 29, 2026, 13:28 ET Plopii bringt nikotinfreie „Focus"-Beutel mit nootropischer Wirkung auf den Markt, deren Wirkstoff Paraxanthin ist
gleichzeitig milderen Auswirkungen auf den Schlaf, die Angstempfindung und die Toleranzentwicklung.Die Formel kombiniert Paraxanthin mit 60 mg Alpha-GPC, 60 mg Citicolin und 60 mg L-Theanin – eine Kombination, die darauf ausgelegt ist, die Aufmerksamkeit sowie eine ruhige, konzentrierte Energie über
More news about: Plopii Inc.
Jun 29, 2026, 12:21 ET Plopii lance des sachets « Focus » nootropiques sans nicotine, à base de paraxanthine
en présentant un profil d'action plus doux en matière de sommeil, d'anxiété et de tolérance.Cette formule associe la paraxanthine à 60 mg d'Alpha-GPC, 60 mg de citicoline et 60 mg de L-théanine, une combinaison conçue pour favoriser la concentration et procurer une énergie sereine et ciblée tout
More news about: Plopii Inc.
Jun 29, 2026, 10:41 ET Plopii Launches Nootropic Nicotine-Free Focus Pouches Powered by Paraxanthine
provide smoother energy and clearer focus with a gentler profile for sleep, anxiety, and tolerance.The formula pairs paraxanthine with 60mg of Alpha-GPC, 60mg of Citicoline, & 60mg of L-theanine, a combination designed to support attention and calm, focused energy throughout the day."We
More news about: Plopii Inc.
Jun 29, 2026, 10:27 ET Plopii Launches Nootropic Nicotine-Free Focus Pouches Powered by Paraxanthine
provide smoother energy and clearer focus with a gentler profile for sleep, anxiety, and tolerance.The formula pairs paraxanthine with 60mg of Alpha-GPC, 60mg of Citicoline, & 60mg of L-theanine, a combination designed to support attention and calm, focused energy throughout the day."We
More news about: Plopii Inc.
Jun 23, 2026, 14:25 ET GCL SI Officially Launches Back-Contact Modules at Intersolar Europe 2026
performance. Mass‑produced GPC cells have achieved an average conversion efficiency of 28.38%, underscoring the company's BC‑track efficiency trajectory.Lower non‑silicon cost via metallization innovation: GPC metallization is a key lever in the GPC 3.0 upgrade. GCL SI also
More news about: GCL SI
Jun 16, 2026, 12:00 ET Grain Management Announces Strategic Combination of Ritter Communications and Great Plains Communications to Form Rightfiber
Plains CommunicationsGreat Plains Communications (GPC), based in Blair, Nebraska, is the leading privately-owned communications and fiber technology provider in the Midwest. Leveraging over a century of experience, GPC delivers a comprehensive suite of fiber-based services, including
More news about: Ritter Communications; Great Plains Communications
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confirmatory Phase II clinical trial in patients with GPC3-positive advanced hepatocellular carcinoma (HCC).
More news about: Oricell Therapeutics Holdings Limited
May 31, 2026, 22:37 ET ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
/PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory hepatocellular carcinoma (HCC). The data,
More news about: Oricell Therapeutics Holdings Limited
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).
More news about: Hackensack Meridian John Theurer Cancer Center
May 25, 2026, 01:46 ET GCL SI and Getz Energy Sign MOU for 1 GW of Advanced PV Modules to Support Thailand's Clean Energy Transition
is engineered to deliver stable, cost-effective performance across the project lifecycle.Meanwhile, the SiRo B Series, built on GCL's advanced GPC technology, combines high conversion efficiency with enhanced visual integration for premium distributed solar applications. Featuring ultra-low reflectivity
More news about: GCL SI
May 21, 2026, 10:11 ET Greater Pacific Capital Announces Leadership Transition in India Business
Christian Hansmeyer as part of the firm's senior leadership team. GPC also announced the promotion of Aditya Ajit, who has been with the firm since 2017, to Vice President.Akshaya Prasad, Managing Director and Co-Head of India for GPC, will step down from his role to pursue an entrepreneurial opportunity.
More news about: Greater Pacific Capital
Apr 29, 2026, 16:37 ET /C O R R E C T I O N -- Barker Wellness/
memory, focus, and cognitive functionFormulated with a blend of Lion's Mane Mushroom, Cordyceps Mushroom, Cognizin, Ginkgo Biloba, Bacopa, Alpha GPC, and Huperzine ANatural Passion Fruit Watermelon Punch flavorBarker Wellness will be available at Target locations nationwide
More news about: Barker Wellness